Connor, Clark & Lunn Investment Management Ltd. Rhythm Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$35.41 - $44.37 $11,862 - $14,863	-335 Reduced 3.46%	9,340 $383,000
Q1 2024 May 09, 2024	SELL	$39.12 - $52.44 $2.19 Million - $2.93 Million	-55,869 Reduced 85.24%	9,675 $419,000
Q4 2023 Feb 09, 2024	SELL	$21.39 - $49.64 $1.41 Million - $3.28 Million	-66,118 Reduced 50.22%	65,544 $3.01 Million
Q3 2023 Nov 13, 2023	BUY	$15.81 - $27.8 $1.16 Million - $2.04 Million	73,543 Added 126.54%	131,662 $3.02 Million
Q2 2023 Aug 10, 2023	BUY	$16.32 - $21.15 $948,502 - $1.23 Million	58,119 New	58,119 $958,000
Q2 2022 Aug 05, 2022	BUY	$3.12 - $12.25 $35,022 - $137,506	11,225 New	11,225 $47,000

Others Institutions Holding RYTM

# of Institutions

191

Shares Held

67.3M

Call Options Held

834K

Put Options Held

78.6K

Primecap Management CO Pasadena, CA

7.22M
Shares

$405 Million
0.28% of portfolio
Black Rock Inc. New York, NY

6.74M
Shares

$379 Million
0.01% of portfolio
Baker Bros. Advisors LP New York, NY

6.4M
Shares

$359 Million
3.59% of portfolio
Ra Capital Management, L.P. Boston, MA

6.08M
Shares

$342 Million
4.44% of portfolio
Goldman Sachs Group Inc New York, NY

3.88M
Shares

$218 Million
0.03% of portfolio

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.13B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account